Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Webcasts|March 31, 2021
Drug Manufacturing During a Global Pandemic
Author(s)AMRI
***Wednesday, March 31, 2021, 11am EDT | 8am PDT | 3pm CEST | 4pm BST*** The COVID-19 pandemic has highlighted the importance of being prepared, planning ahead, and diversifying resources to assure continuity of manufacture and supply of life-sustaining medicines. Learn about best practices to anticipate, manage, and overcome unexpected challenges to drug production during a global emergency. *** On demand available after final airing until March 31, 2022.***
Register free:
Event Overview:
The COVID-19 pandemic has brought into perspective the need for the bio/pharmaceutical industry to plan ahead, diversify supply chains and partner portfolio, and be sufficiently nimble to respond to the unanticipated and immediate needs in fighting a pandemic, as well as assure that the manufacture and supply of life-sustaining medicines spanning all therapeutic areas remains uninterrupted.
Bio/pharmaceutical companies must be prepared for tighter contract manufacturing capacity, pressure to produce drugs domestically, and materials and supply shortages. This webcast will present some of the pressing issues drug companies face, as well as options to mitigate these issues.
Key Learning Objectives:
- Learn ways to manage the shortage of sterile manufacturing capacity contract development and manufacturing organizations as a result of unanticipated COVID-19 work
- Understand the push to keep manufacturing within US borders to help to assure capacity and delivery.
- Review the impact that a shortage of supplies (components, gowning, etc.) has on
Time and Date: Wednesday, March 31, 2021, 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing until March 31, 2022
Sponsor: AMRI
Register free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.